Cochlear Ltd

AU:COH Australia Medical Devices
Market Cap
$7.03 Billion
AU$11.36 Billion AUD
Market Cap Rank
#2182 Global
#15 in Australia
Share Price
AU$173.70
Change (1 day)
+0.36%
52-Week Range
AU$173.07 - AU$319.42
All Time High
AU$345.53
Categories
Companies in Australia Medical Devices
About

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor… Read more

Cochlear Ltd (COH) - Net Assets

Latest net assets as of June 2025: AU$1.95 Billion AUD

Based on the latest financial reports, Cochlear Ltd (COH) has net assets worth AU$1.95 Billion AUD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$2.83 Billion) and total liabilities (AU$874.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$1.95 Billion
% of Total Assets 69.04%
Annual Growth Rate 17.43%
5-Year Change 15.43%
10-Year Change 334.79%
Growth Volatility 20.88

Cochlear Ltd - Net Assets Trend (1996–2025)

This chart illustrates how Cochlear Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Cochlear Ltd (1996–2025)

The table below shows the annual net assets of Cochlear Ltd from 1996 to 2025.

Year Net Assets Change
2025-06-30 AU$1.95 Billion +5.97%
2024-06-30 AU$1.84 Billion +5.24%
2023-06-30 AU$1.75 Billion +3.74%
2022-06-30 AU$1.69 Billion -0.23%
2021-06-30 AU$1.69 Billion +20.56%
2020-06-30 AU$1.40 Billion +93.07%
2019-06-30 AU$725.90 Million +18.84%
2018-06-30 AU$610.80 Million +12.36%
2017-06-30 AU$543.60 Million +21.19%
2016-06-30 AU$448.56 Million +26.22%
2015-06-30 AU$355.39 Million +7.95%
2014-06-30 AU$329.20 Million -7.76%
2013-06-30 AU$356.91 Million -7.27%
2012-06-30 AU$384.88 Million -23.53%
2011-06-30 AU$503.28 Million +14.82%
2010-06-30 AU$438.31 Million +20.34%
2009-06-30 AU$364.23 Million +14.06%
2008-06-30 AU$319.34 Million +22.44%
2007-06-30 AU$260.81 Million +24.33%
2006-06-30 AU$209.78 Million +26.47%
2005-06-30 AU$165.87 Million +13.98%
2004-06-30 AU$145.53 Million +21.59%
2003-06-30 AU$119.69 Million +58.70%
2002-06-30 AU$75.42 Million +35.90%
2001-06-30 AU$55.49 Million +29.57%
2000-06-30 AU$42.83 Million +25.78%
1999-06-30 AU$34.05 Million +6.09%
1998-06-30 AU$32.09 Million +37.71%
1997-06-30 AU$23.31 Million +26.28%
1996-06-30 AU$18.46 Million --

Equity Component Analysis

This analysis shows how different components contribute to Cochlear Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 5368.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Retained Earnings AU$777.30 Million 39.86%
Common Stock AU$1.18 Billion 60.30%
Other Comprehensive Income AU$-3.00 Million -0.15%
Total Equity AU$1.95 Billion 100.00%

Cochlear Ltd Competitors by Market Cap

The table below lists competitors of Cochlear Ltd ranked by their market capitalization.

Company Market Cap
Sociedad Química y Minera de Chile S.A
F:QYM
 		$7.01 Billion
Planet Labs PBC
NYSE:PL
 		$7.01 Billion
Aluminum Corporation of China Limited
PINK:ALMMF
 		$7.01 Billion
Ganfeng Lithium Co Ltd
PINK:GNENF
 		$7.01 Billion
Western Alliance Bancorporation
NYSE:WAL
 		$7.00 Billion
MONDELEZ INTL INC CEDEAR EACH 1
BA:MDLZ
 		$6.99 Billion
ARITZIA INC.SUB.VTG.SHS
F:280
 		$6.99 Billion
Stifel Financial Corporation
NYSE:SF
 		$6.99 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cochlear Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 1,840,500,000 to 1,950,300,000, a change of 109,800,000 (6.0%).
  • Net income of 388,900,000 contributed positively to equity growth.
  • Dividend payments of 278,200,000 reduced retained earnings.
  • Share repurchases of 28,300,000 reduced equity.
  • New share issuances of 100,000 increased equity.
  • Other comprehensive income increased equity by 28,600,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$388.90 Million +19.94%
Dividends Paid AU$278.20 Million -14.26%
Share Repurchases AU$28.30 Million -1.45%
Share Issuances AU$100.00K +0.01%
Other Comprehensive Income AU$28.60 Million +1.47%
Other Changes AU$-1.30 Million -0.07%
Total Change AU$- 5.97%

Book Value vs Market Value Analysis

This analysis compares Cochlear Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 5.83x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 470.58x to 5.83x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1996-06-30 AU$0.37 AU$173.70 x
1997-06-30 AU$0.47 AU$173.70 x
1998-06-30 AU$0.64 AU$173.70 x
1999-06-30 AU$0.67 AU$173.70 x
2000-06-30 AU$0.84 AU$173.70 x
2001-06-30 AU$1.07 AU$173.70 x
2002-06-30 AU$1.44 AU$173.70 x
2003-06-30 AU$2.26 AU$173.70 x
2004-06-30 AU$2.58 AU$173.70 x
2005-06-30 AU$2.97 AU$173.70 x
2006-06-30 AU$3.77 AU$173.70 x
2007-06-30 AU$4.69 AU$173.70 x
2008-06-30 AU$5.73 AU$173.70 x
2009-06-30 AU$6.51 AU$173.70 x
2010-06-30 AU$7.75 AU$173.70 x
2011-06-30 AU$8.83 AU$173.70 x
2012-06-30 AU$6.76 AU$173.70 x
2013-06-30 AU$6.26 AU$173.70 x
2014-06-30 AU$5.77 AU$173.70 x
2015-06-30 AU$6.21 AU$173.70 x
2016-06-30 AU$7.84 AU$173.70 x
2017-06-30 AU$9.46 AU$173.70 x
2018-06-30 AU$10.60 AU$173.70 x
2019-06-30 AU$12.58 AU$173.70 x
2020-06-30 AU$23.50 AU$173.70 x
2021-06-30 AU$25.70 AU$173.70 x
2022-06-30 AU$25.63 AU$173.70 x
2023-06-30 AU$26.54 AU$173.70 x
2024-06-30 AU$28.01 AU$173.70 x
2025-06-30 AU$29.80 AU$173.70 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cochlear Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 19.94%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 16.60%
  • • Asset Turnover: 0.83x
  • • Equity Multiplier: 1.45x
  • Recent ROE (19.94%) is below the historical average (32.66%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1996 58.86% 15.03% 1.50x 2.61x AU$9.02 Million
1997 46.38% 14.82% 1.42x 2.20x AU$8.48 Million
1998 41.39% 0.00% 0.00x 2.15x AU$10.08 Million
1999 47.95% 0.00% 0.00x 2.44x AU$12.92 Million
2000 47.09% 13.99% 1.54x 2.19x AU$15.88 Million
2001 56.18% 14.16% 1.71x 2.33x AU$25.63 Million
2002 53.19% 15.73% 1.59x 2.13x AU$32.57 Million
2003 48.64% 20.17% 1.25x 1.93x AU$46.24 Million
2004 0.45% 0.22% 1.07x 1.90x AU$-13.27 Million
2005 0.72% 0.34% 0.68x 3.14x AU$-14.94 Million
2006 38.56% 17.70% 0.83x 2.63x AU$59.28 Million
2007 38.39% 17.90% 0.96x 2.25x AU$74.05 Million
2008 36.08% 19.15% 0.99x 1.90x AU$83.30 Million
2009 35.84% 18.79% 1.02x 1.87x AU$94.12 Million
2010 35.40% 21.11% 0.98x 1.72x AU$111.32 Million
2011 35.79% 22.25% 1.09x 1.47x AU$129.79 Million
2012 14.76% 7.29% 1.11x 1.83x AU$18.32 Million
2013 37.14% 17.61% 0.98x 2.14x AU$96.87 Million
2014 28.47% 11.64% 1.02x 2.40x AU$60.79 Million
2015 41.04% 15.76% 1.06x 2.46x AU$110.30 Million
2016 42.12% 16.71% 1.18x 2.13x AU$144.07 Million
2017 41.14% 17.84% 1.10x 2.09x AU$169.26 Million
2018 40.24% 18.02% 1.18x 1.89x AU$184.72 Million
2019 38.12% 19.39% 1.03x 1.90x AU$204.11 Million
2020 -17.00% -17.62% 0.52x 1.84x AU$-378.45 Million
2021 19.32% 21.86% 0.62x 1.44x AU$157.54 Million
2022 17.15% 17.62% 0.67x 1.46x AU$120.53 Million
2023 17.19% 15.53% 0.75x 1.47x AU$125.72 Million
2024 19.39% 15.96% 0.81x 1.49x AU$172.75 Million
2025 19.94% 16.60% 0.83x 1.45x AU$193.87 Million

Industry Comparison

This section compares Cochlear Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $8,010,316
  • Average return on equity (ROE) among peers: -356.12%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Cochlear Ltd (COH) AU$1.95 Billion 58.86% 0.45x $7.01 Billion
4DMEDICAL Ltd (4DX) $926.64K -85.93% 0.18x $1.03 Billion
Adherium Ltd (ADR) $34.53 Million -3.63% 0.08x $2.37 Million
Aroa Biosurgery Ltd (ARX) $-22.65 Million 0.00% 0.00x $92.74 Million
Atomo Diagnostics Ltd (AT1) $34.48 Million -26.73% 0.05x $8.96 Million
Control Bionics Ltd (CBL) $6.09 Million -15.97% 0.04x $4.98 Million
Cardiex Ltd (CDX) $3.03 Million -101.61% 0.73x $4.25 Million
Compumedics Ltd (CMP) $9.21 Million -30.70% 1.16x $13.08 Million
Cleo Diagnostics Ltd (COV) $5.83 Million -68.54% 0.19x $23.47 Million
Conneqt Health Limited (CQT) $633.50K -2871.98% 13.72x $4.66 Million